What's Happening?
KalVista Pharmaceuticals has presented new data at the ISPOR 2026 and Eastern Allergy Conference, highlighting the significant burden of injectable on-demand treatments for children aged 2-11 with hereditary angioedema (HAE). The data reveals that the only
FDA-approved treatment for this age group requires intravenous administration, which poses challenges for both children and caregivers. The study found that many families opt for off-label treatments, such as icatibant, due to the invasiveness of injections. The findings emphasize the need for more accessible treatment options, such as oral therapies, to improve the quality of life for affected children and their families.
Why It's Important?
The study underscores the critical need for more child-friendly treatment options for hereditary angioedema, a rare genetic disorder that can cause life-threatening swelling attacks. The current reliance on injectable treatments can lead to significant anxiety and healthcare resource utilization, including emergency room visits. By highlighting these challenges, KalVista aims to drive innovation in the development of oral therapies that could provide a less invasive and more effective solution for managing HAE in children. This could lead to improved adherence to treatment protocols and better health outcomes for young patients.
What's Next?
KalVista is advancing its KONFIDENT-KID trial, which aims to evaluate the safety and efficacy of sebetralstat, an oral on-demand treatment for HAE in children. The company plans to submit a new drug application for this treatment in the third quarter of 2026. If approved, sebetralstat would be the first oral on-demand therapy for children with HAE, potentially transforming the treatment landscape for this condition. The development of such therapies could also set a precedent for addressing similar challenges in other pediatric rare diseases.
